SLG
CTIC

Stanley-Laman Group’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Stanley-Laman Group’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,100
Closed -$14K – 375
2015
Q4 		$14K Buy
+1,100
New +$14.7K ﹤0.01% 352

Other funds holding CTIC

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Stanley-Laman Group's CTIC Position: Q1 2016 in Review

Stanley-Laman Group sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q1 2016, closing a stake of 1,100 shares — an estimated $14K sold.

Stanley-Laman Group first reported a position in CTIC in Q4 2015 and held it in 1 quarter. The position peaked at $14K in Q4 2015. 80 funds tracked by Wall St. Rank hold CTIC as of Q1 2016.

  • Stanley-Laman Group reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q1 2016 after selling out during the quarter.
  • Stanley-Laman Group sold 1,100 CTI BioPharma Corp. (DE) Common Stock shares in Q1 2016, an estimated $14K.
  • Stanley-Laman Group first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2015 and held it in 1 quarter.
  • Stanley-Laman Group's CTI BioPharma Corp. (DE) Common Stock position peaked at $14K in Q4 2015.
  • 80 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q1 2016.

Based on Stanley-Laman Group's 13F filing for Q1 2016, filed 9 May 2016.